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Abstract
Polo-like kinase 1 (Plk1) plays key roles in regulating various mitotic processes that are critical for cellular proliferation. A
growing body of evidence suggests that Plk1 overexpression is tightly associated with the development of human
cancers. Interestingly, various types of cancer cells are shown to be addicted to a high level of Plk1, and the reversal of
Plk1 addiction appears to be an effective strategy for selectively killing cancer cells, but not normal cells. Therefore, Plk1
is considered an attractive anticancer drug target. Over the years, a large number of inhibitors that target the catalytic
activity of Plk1 have been developed. However, these inhibitors exhibit significant levels of cross-reactivity with related
kinases, including Plk2 and Plk3. Consequently, as an alternative approach for developing anti-Plk1 therapeutics,
substantial effort is under way to develop inhibitors that target the C-terminal protein–protein interaction domain of
Plk1, called the polo-box domain (PBD). In this communication, I will discuss the pros and cons of targeting the PBD in
comparison to those of targeting the ATP-binding site within the kinase domain.
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Review
Protein phosphorylation by protein kinases represents a
fundamental mechanism underlying diverse biochemical
and cellular processes that are important for the prolifera-
tion of eukaryotic cells (Hanks et al. 1988). Protein kinases
are a family of enzymes that catalyze the transfer of the
gamma phosphate from adenosine triphosphate (ATP) to
a protein substrate and, as a result, induce a change in the
conformation and function of the protein substrate. A
large body of evidence suggests that deregulating this
process can lead to various pathological disorders in
humans, including cancers (Lahiry et al. 2010). Therefore,
deregulated protein kinases may represent attractive tar-
gets for the development of therapeutics against various
human disorders. However, unlike initial expectations, tar-
geting protein kinases has proven difficult largely because
of the similarities in their primary sequences and con-
served structural motifs around the ATP-binding site.
Nevertheless, recent advances in our understanding of this
family of enzymes have allowed us to overcome these
obstacles and develop a sizable number of clinically
applicable therapeutic agents. According to the Protein
Kinase Inhibitors in Oncology Drug Pipeline Update 2015,
small-molecule inhibitors were reported against nearly
half of a total of 518 cellular protein kinases. Among
them, more than 35 inhibitors are approved by the US
Food and Drug Administration for clinical applications,
and approximately 500 inhibitors are currently in clinical
trials for further development.
Although developing inhibitors that target the catalytic
activity of a protein kinase has become a prevailing
method, various efforts are under way to develop inhibi-
tors that target a functionally critical protein–protein
interaction domain of a kinase. This newly emerging strat-
egy, which is thought to yield a higher level of specificity
than conventional ATP analog inhibitors, may lead to the
development of a different class of inhibitors that could be
used either alone or in combination with available cata-
lytic inhibitors to achieve increased drug efficacy.
Polo-like kinases
Polo-like kinases (collectively known as Plks) belong
to the evolutionarily conserved polo subfamily of Ser/
Thr protein kinases that play pivotal roles in cell
proliferation, differentiation, and adaptive responses
(see reviews; Winkles and Alberts 2005; Petronczki
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et al. 2008; Archambault and Glover 2009; Zitouni
et al. 2014). In mammalian cells, five Plks (Plk1–5) were
identified to date (Fig. 1a), and they exhibit distinct tissue
distributions and physiological functions. Except for Plk4,
these members contain a signature domain, called the
polo-box domain (PBD), which is composed of two motifs
with significant homology—polo-box 1 (PB1; residues
405–494 in Plk1) and polo-box 2 (PB2; residues 505–598
in Plk1). Plk4 contains the distantly related cryptic polo
box (CPB) and PB3 domains, which interact with its bind-
ing targets (Leung et al. 2002; Park et al. 2014).
Among them, Plk1 has drawn a lot of attention because
of its tight association with tumorigenesis in human cells.
Various studies have shown that Plk1 is highly expressed
during the G2 and M phases of the cell cycle (Golsteyn
et al. 1995; Lee et al. 1995), and it plays an important role
in regulating mitotic entry, centrosome maturation and bi-
polar spindle assembly, metaphase/anaphase transition,
and cytokinesis (Winkles and Alberts 2005; Petronczki
et al. 2008; Archambault and Glover 2009; Zitouni et al.
2014) (Fig. 1b). Consistent with the multitude of Plk1
functions, Plk1 has been shown to localize to distinct
Fig. 1 The human Plk family and the function and subcellular localization of Plk1 during the cell cycle. a A schematic diagram illustrating the
structures of the human Plk family. Sequence identity (%) with Plk1 is shown. PB1 polo-box motif 1, PB2 polo-box motif 2, CPB cryptic polo
box, PB3 polo-box motif 3. Numbers, amino acid residue numbers for each Plk. b A schematic diagram depicting the mitotic functions of Plk1
from G2/M transition to cytokinesis. c Subcellular localization of Plk1 in HeLa cells during the cell cycle. Kinetochore-localized Plk1 signals are
colocalized with CREST antigens. Asterisks centrosomes. These images were originally published in Journal of Biological Chemistry. Seong YS,
et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. 2002;
277(35):32282-93. © the American Society for Biochemistry and Molecular Biology
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subcellular structures, such as centrosomes, kinetochores,
and midzones/midbodies, in a temporally and spatially
regulated manner (Holtrich et al. 1994; Golsteyn et al.
1995; Lee et al. 1995; Arnaud et al. 1998; Seong et al.
2002) (Fig. 1c). The PBD is largely responsible for direct-
ing its catalytic activity of Plk1 to specific subcellular loca-
tions (Lee et al. 1998; see review; Park et al. 2010) via its
capacity to interact with a phosphorylated Ser/Thr motif,
thereby bringing the enzyme in close proximity to its
binding targets or substrates localized at these sites
(Cheng et al. 2003; Elia et al. 2003; Lowery et al. 2004;
Park et al. 2010). As expected, the function of Plk1
PBD is essentially required for proper mitotic progres-
sion (Lee et al. 1998, 1999; Seong et al. 2002; Hanisch
et al. 2006). As of today, a large number of PBD-
binding proteins critically required for various Plk1-
dependent mitotic events have been isolated and
characterized (Park et al. 2010). Thus, the PBD serves
as an essential cis-acting element that mediates vari-
ous Plk1-dependent biochemical steps and cellular
processes at specific subcellular structures.
Distinct from the roles of Plk1 during the late stage of
the cell cycle, Plk2 appears to be transiently expressed in
G1 and contributes to proper S-phase entry (Simmons
et al. 1992; Ma et al. 2003a, b). Other studies showed that
Plk2 plays a role in maintaining cell viability after spindle
poisoning (Burns et al. 2003). Interestingly, Plk3 is
expressed throughout the cell cycle (Chase et al. 1998)
and has been implicated in responding to DNA damage
and cellular stress (Donohue et al. 1995; Xie et al. 2001a,
b, 2002, 2005; Bahassi et al. 2002). Both Plk2 and Plk3 are
proposed to function as tumor suppressors (Smith et al.
2006; Yang et al. 2008). On the other hand, Plk4 has been
shown to function as a key regulator of centriole biogen-
esis at the early stage of the cell cycle (Bettencourt-Dias
et al. 2005; Habedanck et al. 2005; Duensing et al. 2007;
Kleylein-Sohn et al. 2007), suggesting that Plk4-dependent
centriole duplication lays a groundwork for Plk1-
dependent centrosome maturation and bipolar spindle
formation at the time of mitotic entry.
Plk1: a cancer cell-selective anticancer drug target
Consistent with the important role of Plk1 in regulating
various mitotic events, Plk1 overexpression is thought to
promote neoplastic transformation of human cells
(Eckerdt et al. 2005; Strebhardt and Ullrich 2006; Streb-
hardt 2010). Not surprisingly, Plk1 overexpression ap-
pears to be tightly associated with aggressiveness and
poor prognosis of various types of human cancers. In
addition, recent genome-wide studies have revealed that
Plk1 and a number of other mitotically important regu-
lators, such as the anaphase-promoting complex/cyclo-
somes and the proteasome, are required for the viability
of activated RAS or inactivated TP53 mutation-bearing
cancer cells, but not for the respective normal cells
(Luo et al. 2009a; Sur et al. 2009). These observations
suggest that cancer cells are addicted not only to onco-
genic RAS or the inactivated p53 function, as Bernard
Weinstein originally proposed (Weinstein 2002), but also
to non-oncogenic Plk1, whose inhibition results in prome-
taphase accumulation and subsequent death (Luo et al.
2009b) (Fig. 2). These observations suggest that Plk1-
dependent biochemical steps and signaling pathways are
likely reprogrammed for the survival and proliferation of
Plk1-addicted cancer cells. Under these conditions, the re-
versal of Plk1 addiction may be sufficient for triggering
cancer cell-selective mitotic block and apoptotic cell death
(Luo et al. 2009b), as has been demonstrated by the rever-
sal of oncogene addictions (McMurray et al. 2008). As an
alternative explanation to the oncogene (and also perhaps
non-oncogene) addiction, Dean Felsher proposed that
oncogene activation may induce a state of cellular
amnesia, which allows cells to bypass surveillance mecha-
nisms and, therefore, permits unregulated cell proliferation
(Felsher 2008). Whether the altered cellular homeostasis
in cancer cells is called addiction or amnesia, studies
suggest that the reversal of Plk1 addiction is sufficient
for inducing selective cellular senescence or apoptosis
in oncogenic RAS- or inactivated TP53-containing can-
cer cells (Luo et al. 2009a; Sur et al. 2009) (Fig. 2).
Therefore, antagonizing the Plk1 function appears to be
Fig. 2 A schematic diagram illustrating hypothetical biochemical pathways between normal cells and Plk1-addicted cancer cells bearing an oncogenic
RAS and/or a TP53 loss-of-function mutation. Reversal of Plk1 addiction (or gaining self-consciousness from Plk1 amnesia) may induce cancer
cell–selective mitotic arrest and apoptotic cell death
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a particularly appealing strategy for killing oncogenic
RAS- or inactivated TP53-containing cancer cells. Since
both Plk2 and Plk3 are required for promoting cell sur-
vival (Burns et al. 2003; Xie et al. 2005) and they exhibit
properties similar to tumor suppressors (Smith et al.
2006; Yang et al. 2008; Coley et al. 2012), specific inhib-
ition of Plk1, but not Plk2 or Plk3, would be important
for selectively killing cancer cells, but not normal cells.
Targeting the kinase domain vs. the PBD of Plk1
Both the kinase domain (KD) and PBD of Plk1 are
essentially required for the mitotic functions of Plk1
(Lee et al. 1998; Seong et al. 2002; Hansen et al. 2004),
suggesting that they represent two distinct drug targets
within one molecule (Fig. 3). The ATP-binding pocket
within the KD serves as a well-defined target site that
may allow one to achieve the complete annihilation of
the kinase’s catalytic activity. Consequently, targeting the
ATP-binding site has long been a prevailing method for
generating kinase inhibitors. Over the years, several ATP
analog inhibitors (e.g., BI2536, BI6727, GSK461364A,
cyclapolin 1, DAP81, and TAL) have been developed to
competitively inhibit Plk1 catalytic activity. BI6727 (also
called volasertib) is the most advanced and has been
evaluated under phase III clinical trials. However, be-
cause of the structural similarities among the catalytic
domains of >500 intracellular kinases, these inhibitors
largely exhibit a broad inhibitory activity against
closely related Plk2 and Plk3 and several other ki-
nases (Steegmaier et al. 2007; Rudolph et al. 2009;
Raab et al. 2014), therefore frequently limiting their in
vivo applicability because of poor pharmacological safety
profiles and dose-limiting toxicity (Lee et al. 2015).
As a new approach to bypass the problems associated
with currently available KD inhibitors, a large body of
studies has been performed to generate Plk1 PBD antag-
onists. This new approach is important because targeting
protein–protein interactions is considered a highly at-
tractive strategy that provides a potential for developing
specific inhibitors against a particular protein. However,
finding a targetable protein–protein interaction motif
with a distinct binding nature is thought to be difficult
because binding surfaces are mostly nondescript. Against
the odds, studies with Plk1 PBD revealed that a small
and specific phosphopeptide is sufficient for interacting
with Plk1 PBD, but not with PBDs from Plk2 or Plk3,
with a high affinity (Elia et al. 2003; Yun et al. 2009),
suggesting that specific inhibition of Plk1 PBD could be
achieved by low-molecular weight, peptide-derived
inhibitors, or structurally related compounds. Moreover,
recent data suggests that interrogating Plk1 PBD
function by expressing a highly specific, suicidal PBD-
binding peptide can potently induce mitotic block and
apoptosis in tumorigenic or metastatic cancer cells, but
not in normal cells (Park et al. 2015). Albeit this promis-
ing outlook, small-molecule PBD inhibitors developed to
date (Reindl et al. 2008; Watanabe et al. 2009) exhibit
only suboptimal Plk1 PBD-binding affinity with an un-
defined binding mode (Liao et al. 2010). On the other
hand, peptide-derived Plk1 PBD inhibitors exhibit su-
perb binding affinity and specificity in vitro. However,
they suffer greatly from poor membrane permeability
and low bioavailability in cell-based assays (Liu et al.
2011; Qian et al. 2014), thus necessitating further im-
provement of these inhibitors for in vivo studies.
Advantages of targeting the PBD of Plk1
Besides being an alternative target for anti-Plk1 drug dis-
covery, it is important to note that inhibiting the PBD is
fundamentally different from inhibiting the KD, at both
physiological and biochemical levels. Studies showed
that inhibiting Plk1 catalytic activity potently induces
early mitotic arrest (Sumara et al. 2004; Hanisch et al.
2006; Lenart et al. 2007), whereas inhibiting Plk1 PBD
function results in preanaphase arrest (Seong et al. 2002;
Hanisch et al. 2006). These findings suggest that this
Plk1 kinase activity-dependent process is essentially re-
quired from the early stage of mitosis, whereas the PBD-
dependent Plk1 function is essential only at a much later
stage but prior to the metaphase/anaphase transition. At
the biochemical level, the KD binds to ATP as the only
ligand, whereas the PBD binds to a large spectrum of
binding targets, such as Plk1-binding proteins and
physiological substrates (Park et al. 2010). Moreover, the
PBD binds to its various targets with different levels of
affinity, thus enabling the PBD to mediate diverse Plk1-
dependent events in a differentially regulated manner.
These fundamental differences in the biochemical prop-















Fig. 3 A schematic diagram illustrating two distinct strategies for
targeting Plk1. ATP-competitive analogs have been widely developed
to inhibit the catalytic activity of Plk1, while PBD-binding antagonists
are being developed to competitively inhibit the function of PBD. KD
kinase domain, PBD polo-box domain. In the diagram, the PBD is
shown to interact with a phosphorylated epitope on a substrate, and it
tethers the cis-acting N-terminal KD in close proximity to its substrate.
ATP adenosine triphosphate, ADP adenosine diphosphate
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inhibitors would annihilate Plk1 catalytic activity in both
normal and cancer cells equally, whereas PBD inhibitors
could interfere with only a subset of PBD-dependent
interactions. Since Plk1-dependent signaling pathways
and biochemical steps are predictably rewired in Plk1-
addicted cancers, it would be feasible to tailor PBD in-
hibitors in such a way that they would interfere with
PBD-dependent interactions enriched in cancer cells,
but not normal cells. Therefore, unlike inhibiting Plk1
KD, antagonizing the PBD function may allow one to
uniquely impose an additional layer of selectivity in kill-
ing cancer cells, but not normal cells.
Recent advances in developing Plk1 PBD inhibitors
During the past several years, numerous independent ef-
forts have been made to generate both small-molecule-
and peptide-based PBD inhibitors (Lee et al. 2015).
Small-molecule inhibitors were isolated from in vitro
screenings designed to isolate compounds capable of
disrupting the Plk1 PBD-dependent interaction with its
cognate peptide ligand. These small-molecule inhibitors
include a thymoquinone derivative, poloxin (Reindl et al.
2008), a benzylidene-thiazolotriazenedione derivative,
poloxipan (Reindl et al. 2009), and a benzotropolone de-
rivative, purpurogallin (Watanabe et al. 2009). However,
these inhibitors exhibit only weak inhibitory activity
against Plk1 PBD in vitro (Liao et al. 2010), with a sub-
stantial level of nonspecific toxicity in cultured cells
(Park, J. -E, and K. S. Lee, unpublished data), suggesting
that their applicability is likely limited. Optimizing these
inhibitors to improve both Plk1 PBD-binding affinity
and specificity would be necessary in order to use them
in preclinical and clinical studies. The co-crystal struc-
tures of Plk1 PBD, in complex with the structurally simi-
lar thymoquinone or the oxime fragment of poloxin
(called poloxime), have been determined (Yin et al.
2013). The binding mode of thymoquinone or the oxime
fragment may potentially serve as a template for anti-
PBD drug discovery.
Studies with various PBD-binding proteins led to the
identification of a peptide as small as 5-mer PLHSpT
(Yun et al. 2009). This peptide was identified from the
T78 motif of a kinetochore component called PBIP1
(Kang et al. 2006). PLHSpT falls into the consensus
Plk1 PBD-binding target that was previously reported
(Elia et al. 2003) and binds to Plk1 PBD with high af-
finity and specificity (Kd = 450 nM) (Yun et al. 2009).
Over the years, substantial progress has been made in
developing various PLHSpT derivatives with improved
affinity and/or cellular activity (Liu et al. 2011, 2012a,
b; Qian et al. 2012, 2014; Murugan et al. 2013a, b;
Srinivasrao et al. 2014; Ahn et al. 2015). Among these
derivatives, a C6H5(CH2)8 group-conjugated 4j (Fig. 4a)
is considered a prototype, and it exhibits dramatically
increased (~500-fold) affinity (Kd = 1–2 nM) with an un-
diminished level of Plk1-binding specificity (Liu et al.
2011). The unexpected binding mode between the
alkylphenyl moiety of 4j and neighboring hydrophobic
residues of Plk1 PBD may provide a new paradigm in
the development of Plk1 PBD-binding inhibitors. In
addition, the N-terminal Pro motif has been shown to
confer Plk1 specificity and ~20-fold affinity to Plk1
PBD, while the C-terminal SpT dipeptide functions as
a high-affinity anchor that is crucially required for
A B
Fig. 4 The mode of binding between Plk1 PBD and its high-affinity ligand, 4j. a Electrostatic surface representation of the Plk1 PBD in complex
with 4j. Surface colors represent electrostatic potentials with red (negative), blue (positive), and white (neutral). For 4j, oxygen and nitrogen atoms
are colored in red and blue, respectively. The alkylphenyl moiety is indicated in violet. The phosphorylated (red)-T residue is shown. b A schematic
diagram showing 4j and its three elements, which are critical for Plk1 PBD binding. PLHSpT is shown in single letters except for phosphorylated
(red)-T. The alkylphenyl moiety of 4j is indicated in violet
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establishing a stable interaction with the H538 and
K540 residues of Plk1 PBD (Yun et al. 2009) (Fig. 4b).
Although they exhibit superb binding affinity and spe-
cificity, 4j and its derived inhibitors (Liu et al. 2011,
2012a, b; Qian et al. 2012, 2014) still require high
extracellular concentrations (IC50 = 80–320 μM) to
delocalize Plk1 and induce mitotic block in cultured
HeLa cells. This requirement appears to be largely due to
these inhibitors’ less than acceptable level of membrane
permeability and intracellular stability (Liu et al. 2011).
Further derivatization and optimization of these inhibitors
would be necessary to improve the bioavailability and effi-
cacy of the compounds.
Whether improving peptide-based inhibitors can lead
to the development of more clinically applicable PBD
antagonists remain to be seen. Nevertheless, the novel
binding interactions within the C6H5(CH2)8 group may
likely be critical for the future design of PBD-binding
antagonists. Based on the earlier success in generating a
PLHSpT-based cyclic peptomer (Murugan et al. 2013b),
developing 4j-based cyclic peptides and their derivatives
could be important not only to their direct use for in
vitro and/or in vivo applications, but also to the design
and development of more druggable small-molecule-
based inhibitors.
Conclusions
It is now well appreciated that targeting PBD constitutes
a fascinating strategy that may lead to the development
of a new class of Plk1 inhibitors. Although substantial
progress has been made in developing Plk1 PBD inhibi-
tors during the last several years, these inhibitors suffer
greatly from low binding affinity, poor specificity, or low
membrane permeability. Nevertheless, studies with peptide-
based inhibitors revealed that high-affinity and high-
specificity binding to Plk1 PBD can be achieved by
several structural motifs, such as the SpT high-affinity
anchor, the N-terminal Pro moiety, and the recently
discovered hydrophobic channel-based interactions. At
present, one of the biggest challenges in developing
4j-based inhibitors is improving membrane permeabil-
ity by minimizing the anionic change of the phos-
phorylated Thr residue that is critical for PBD
binding. Although developing 4j-based inhibitors may
have its own merits, it may be important to design
and develop next-generation small-molecule PBD
inhibitors that mimic the structure of 4j or its
derivatives.
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